ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 699,77
-0,30%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. POINT Biopharma Global Inc (PNT)

  7. POINT Biopharma Global Inc (PNT) Actualités

PNT POINT Biopharma Global Inc

12,50
0,00 (0,00%)
03 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
POINT Biopharma Global Inc PNT NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 12,50 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
12,50 12,50
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
08/1/202413:00EDGAR2Form 15-12G - Securities registration termination [Section..
03/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
27/12/202323:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202323:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202323:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202323:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202323:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202323:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202323:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202323:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202315:44EDGAR2Form POS AM - Post-Effective amendments for registration..
27/12/202315:43EDGAR2Form POS AM - Post-Effective amendments for registration..
27/12/202315:42EDGAR2Form S-8 POS - Securities to be offered to employees in..
27/12/202314:54EDGAR2Form 8-K - Current report
27/12/202314:31PRNUSLilly Completes Acquisition of POINT Biopharma
18/12/202314:14EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
18/12/202313:30GLOBELantheus and POINT Biopharma Announce Positive Topline..
18/12/202312:45PRNUSLilly Extends Tender Offer to Acquire POINT Biopharma to..
05/12/202312:25IHMARKETNEWSMoody’s Reassesses China, GitLab Exceeds Estimates, Twilio..
04/12/202313:22EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
04/12/202312:45PRNUSLilly Extends Tender Offer to Acquire POINT Biopharma to..
17/11/202313:05EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
17/11/202312:45PRNUSLilly Extends Tender Offer to Acquire POINT Biopharma to..
15/11/202313:00EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
14/11/202322:33PRNUSLilly Announces the Receipt of NRC Consent in Connection..
13/11/202313:30GLOBEPOINT Biopharma Reports Third Quarter 2023 Financial Results..
13/11/202313:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202323:28EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
08/11/202322:56PRNUSLilly Announces Extension of Tender Offer to Acquire POINT..
08/11/202300:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202323:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/11/202321:40EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
27/10/202322:20EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
13/10/202313:11EDGAR2Form SC 14D9 - Solicitation, recommendation statements
03/10/202323:24EDGAR2Form SC14D9C - Written communication relating to third party..
03/10/202316:03IHMARKETNEWSKeep An Eye Out: Pre-Market Movers And Recommendations
03/10/202313:37EDGAR2Form SC14D9C - Written communication relating to third party..
03/10/202313:35EDGAR2Form 8-K - Current report
03/10/202312:45PRNUSLilly to Acquire POINT Biopharma to Expand Oncology..
18/9/202314:00GLOBEPOINT Biopharma and Athebio Announce Partnership to Develop..
14/8/202316:22EDGAR2Form S-8 - Securities to be offered to employees in employee..
14/8/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202313:30GLOBEPOINT Biopharma Reports Second Quarter 2023 Financial..
14/8/202313:21EDGAR2Form 8-K - Current report
03/8/202322:05EDGAR2Form 8-K - Current report
31/7/202315:00GLOBEITM and POINT Biopharma Expand Global Supply Agreement for..
26/6/202313:45GLOBEPOINT Biopharma and AdvanCell to Collaborate in the..
26/6/202313:30GLOBEPOINT Biopharma Expands Its Research with Next-Generation..
12/6/202314:00GLOBEPOINT Biopharma Announces Appointment of Dr. Bridget Martell..
07/6/202313:00GLOBEPOINT Biopharma to Host Virtual Investor Day on Tuesday,..

Dernières Valeurs Consultées

NASDAQ
PNT
POINT Biopharma Global
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés